Skip to content
10-Q

Quarterly Report

OptimizeRx Corp OPRX

0001448431-25-000005

← back to feed
Filed
May 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 6, 2025 18.5M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $29.19M
Long Term Debt Q1 2025 · Dec 31, 2024 $30.82M
Short Term Debt Q1 2025 · Mar 31, 2025 $3.3M
Short Term Debt Q1 2025 · Dec 31, 2024 $2M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $16.57M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $13.38M
Current Liabilities Q1 2025 · Mar 31, 2025 $18.35M
Current Liabilities Q1 2025 · Dec 31, 2024 $18.65M
Total Liabilities Q1 2025 · Mar 31, 2025 $51.5M
Total Liabilities Q1 2025 · Dec 31, 2024 $54.17M
Current Assets Q1 2025 · Mar 31, 2025 $51.71M
Current Assets Q1 2025 · Dec 31, 2024 $53.97M
Total Assets Q1 2025 · Mar 31, 2025 $167.77M
Total Assets Q1 2025 · Dec 31, 2024 $171.17M
Gross Profit Q1 2025 · Mar 31, 2025 $13.34M
Gross Profit Q1 2025 · Mar 31, 2024 $12.2M
Shares Diluted Q1 2025 · Mar 31, 2024 18.17M sh
Capex Q1 2025 · Mar 31, 2024 $32K
Operating Cash Flow Q1 2025 · Mar 31, 2024 $2.12M
Stockholders Equity Q1 2025 · Mar 31, 2024 $122.54M
Stockholders Equity Q1 2025 · Dec 31, 2023 $126.55M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.38
Eps Basic Q1 2025 · Mar 31, 2024 −$0.38
Net Income Q1 2025 · Mar 31, 2024 −$6.9M
Operating Income Q1 2025 · Mar 31, 2024 −$5.03M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $7.49M